Interestingly, whole-genome CRISPR screening in a resistant mesenchymal cell line established from biopsies of NSCLC patients who progressed on 3rd G EGFR-TKIs (41) identified FGFR1 as the top sensitization target of EGF816-resistant cells. This evidence concerns the gene EGFR and non-small cell lung carcinoma.